載入...
ES-2 Phase 3 TRIDENT Trial: Radiation and Temozolomide with or without Tumor Treating Fields in newly diagnosed glioblastoma
Background: Tumor treating fields (TTFields) is a non-invasive, regional antimitotic treatment approved as a standard-of-care for glioblastoma. In the EF-14 Phase 3 trial, TTFields (200 kHz) plus temozolomide (TMZ) significantly increased survival of patients with newly diagnosed GBM(ndGBM) without...
Na minha lista:
| 發表在: | Neurooncol Adv |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7699074/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.011 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|